| Dear Subscriber, |
| Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories. To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y . |
| Aid / Disasters News | |
| Refugees Can Be Effectively Treated To Prevent Tuberculosis Almost one in three recently arrived refugees in Darwin tested positive for latent tuberculosisinfection (LTBI), research published in the latest Medical Journal of Australia has found. Researchers from the Centre for Disease Control, Northern Territory (CDC-NT) found that of458 refugees screened between 1 February 2006 and 31 January 2009, 146 (31. | 04 June 2011 |
| Anxiety / Stress News | |
| Letters From Home May Help Prevent Posttraumatic Stress Disorder In Happily Married Soldiers A new study from The Journal of Traumatic Stress finds that for active-duty male soldiers in the U.S. Army who are happily married, communicating frequently with one's spouse through letters and emails during deployment may protect against the development of posttraumatic stress disorder (PTSD) symptoms after returning home. | 04 June 2011 |
| Breast Cancer News | |
| Aromasin (exemestane) Reduces Breast Cancer Risk In Postmenopausal Women, Study Exemestane (Aromasin), an aromatase inhibitor, was found to lower invasive breast cancer rates by 65% in moderate and high-risk postmenopausal females, researchers at the Massachusetts General Hospital Cancer Center in Boston reported. | 04 June 2011 |
| Leading Breast Cancer Researcher And Study Co-Author Rowan T. Chlebowski Explains Seemingly Contradictory Findings On Estrogen And Breast Cancer Rowan T. Chlebowski, M.D., Ph.D., a principal investigator at the Los Angeles Biomedical Research Institute (LA BioMed), provided his assessment of the seeming contradictions between a previous Women's Health Initiative (WHI) study and a new abstract to be presented June 4 at the 2011 American Society of Clinical Oncology. | 04 June 2011 |
| Cancer / Oncology News | |
| Talactoferrin Benefits Broad Range Of Lung Cancer Patients The investigational immunomodulatory agent talactoferrin boosts survival compared to placebo in multiple prognostically important subsets of patients with non-small cell lung cancer (NSCLC) who have failed first- or second-line therapy, according to phase II data released at the 2011 American Society of Clinical Oncology (ASCO) meeting. | 04 June 2011 |
| Aromasin (exemestane) Reduces Breast Cancer Risk In Postmenopausal Women, Study Exemestane (Aromasin), an aromatase inhibitor, was found to lower invasive breast cancer rates by 65% in moderate and high-risk postmenopausal females, researchers at the Massachusetts General Hospital Cancer Center in Boston reported. | 04 June 2011 |
| Understanding Cancer Energetics It's long been known that cancer cells eat a lot of sugar to stay alive. In fact, where normal, noncancerous cells generate energy from using some sugar and a lot of oxygen, cancerous cells use virtually no oxygen and a lot of sugar. | 04 June 2011 |
| Matching Targeted Therapies To Tumor's Specific Gene Mutations May Be Key To Personalized Cancer Treatment Customizing targeted therapies to each tumor's molecular characteristics, instead of a one-size-fits-all approach by tumor type, may be more effective for some types of cancer, according to research conducted by The University of Texas MD Anderson Cancer Center. | 04 June 2011 |
| Leading Breast Cancer Researcher And Study Co-Author Rowan T. Chlebowski Explains Seemingly Contradictory Findings On Estrogen And Breast Cancer Rowan T. Chlebowski, M.D., Ph.D., a principal investigator at the Los Angeles Biomedical Research Institute (LA BioMed), provided his assessment of the seeming contradictions between a previous Women's Health Initiative (WHI) study and a new abstract to be presented June 4 at the 2011 American Society of Clinical Oncology. | 04 June 2011 |
| Study Identifies Genetic Mutations Associated With Cancer Risk For Hereditary Cancer Syndrome Among various genetic mutations for individuals with Lynch syndrome, a hereditary cancer syndrome that carries a high risk of colon cancer and an above-normal risk of other cancers, researchers have identified mutations associated with a lower cancer risk and mutations associateded with an increased risk for ovarian and endometrial cancer, according to a study in the June 8 issue of JAMA, a theme issue on cancer. | 04 June 2011 |
| Following Colorectal Cancer Surgery, Longer Delay To Beginning Chemotherapy Associated With Worse Survival An analysis of data from previously published studies indicates that longer time to beginning adjuvant chemotherapy after surgery for colorectal cancer is associated with worse survival, according to a study in the June 8 issue of JAMA, a theme issue on cancer. | 04 June 2011 |
| Childhood Cancer Survivors At Increased Risk Of Certain Tumors In Middle-Age In a study that included nearly 18,000 children who had cancer, with follow-up of about 25 years, the greatest excess risk associated with a subsequent primary neoplasm (a new tumor) at older than age 40 years was for digestive and genitourinary neoplasms (related to the genital or urinary tract organs), according to a study in the June 8 issue of JAMA, a theme issue on cancer. | 04 June 2011 |
| Cardiovascular / Cardiology News | |
| Mount Sinai Medical Center Selected To Participate In CoreValve® Clinical Trial Mount Sinai Medical Center in Miami Beach, Florida announced its participation in the Medtronic CoreValve U.S. Clinical Trial, which will evaluate a new, non-surgical alternative to open-heart surgery for patients with severe aortic stenosis. | 04 June 2011 |
| New Treatment Hope For Diabetes And Cardiovascular Diseases New research at the University of Leicester to contribute to more effective drug design.A cutting-edge research project at the University of Leicester is aiming to improve the treatment of diabetes and cardiovascular diseases. | 04 June 2011 |
| Immune Cells Secrete A Signal Molecule That Promotes Atherosclerosis Atherosclerosis is the most common cause of cardiovascular disease, and results from chronic inflammation of arterial vessel walls. An international collaboration led by Professor Christian Weber of Ludwig-Maximilians-Universität (LMU) in Munich and Privatdozentin Alma Zernecke of Würzburg University now shows that dendritic cells stimulate this process by derailing a mechanism that normally acts as a brake on immune reactions. | 04 June 2011 |
| Pulmonary Thromboembolism Deaths And Obesity May Be Linked More people are dying from pulmonary thromboembolism (PTE), and this could be associated with parallel rises in obesity rates, researchers from the University of Adelaide Roger Byard wrote in the Medical Journal of AustraliaProfessor Roger Byard and co-author explain that while focus should continue on illnesses and conditions linked to obesity, such as cardiac disease, hypertension (high blood pressure), and diabetes mellitus, doctors should also concentrate on PTE. | 04 June 2011 |
| Clinical Trials / Drug Trials News | |
| Medco Partners With MolecularMD On Personalized Medicine Program For Chronic Myeloid Leukemia Medco Health Solutions, Inc. (NYSE: MHS) and MolecularMD Corp. announce the launch of a personalized medicine program for chronic myeloid leukemia (CML) patients. Through this program, Medco will offer patients diagnosed with CML a molecular test known as qRT-PCR (quantitative real-time polymerase chain reaction) BCR-ABL to monitor the disease. | 04 June 2011 |
| Wake Forest Baptist Medical Center And Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial Of CPI-613 In Acute Myeloid Leukemia Cornerstone Pharmaceuticals and Wake Forest Baptist Medical Center announced key findings from a Phase I clinical trial of Cornerstone's first-in-class cancer metabolism inhibitor drug, CPI-613 in Acute Myeloid Leukemia (AML). | 04 June 2011 |
| Everist Genomics Announces New Data On OncoDefender™- CRC Test For Predicting Recurrence Risk For Stage I And II Colorectal Cancer Patients Everist Genomics announced updated results from a study of its OncoDefender-CRC assay, a molecular prognostic test for early-stage colorectal cancer patients, will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2011, in Chicago. | 04 June 2011 |
| EntreMed's ENMD-2076 Demonstrates Clinical Activity In Recurrent, Platinum-Resistant Ovarian Cancer Patients EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients. | 04 June 2011 |
| Mount Sinai Medical Center Selected To Participate In CoreValve® Clinical Trial Mount Sinai Medical Center in Miami Beach, Florida announced its participation in the Medtronic CoreValve U.S. Clinical Trial, which will evaluate a new, non-surgical alternative to open-heart surgery for patients with severe aortic stenosis. | 04 June 2011 |
| Colorectal Cancer News | |
| Everist Genomics Announces New Data On OncoDefender™- CRC Test For Predicting Recurrence Risk For Stage I And II Colorectal Cancer Patients Everist Genomics announced updated results from a study of its OncoDefender-CRC assay, a molecular prognostic test for early-stage colorectal cancer patients, will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2011, in Chicago. | 04 June 2011 |
| Following Colorectal Cancer Surgery, Longer Delay To Beginning Chemotherapy Associated With Worse Survival An analysis of data from previously published studies indicates that longer time to beginning adjuvant chemotherapy after surgery for colorectal cancer is associated with worse survival, according to a study in the June 8 issue of JAMA, a theme issue on cancer. | 04 June 2011 |
| Diabetes News | |
| New Treatment Hope For Diabetes And Cardiovascular Diseases New research at the University of Leicester to contribute to more effective drug design.A cutting-edge research project at the University of Leicester is aiming to improve the treatment of diabetes and cardiovascular diseases. | 04 June 2011 |
| Ear, Nose and Throat News | |
| Masimo Initiates Limited Market Release Of E1, Single-Patient-Use Ear Sensor For Pulse Oximetry Monitoring Masimo (NASDAQ: MASI) announced FDA 510(k) Clearance, CE Mark, and limited market release of the industry's first single-patient-use ear sensor. Compared to digit sensors, the Masimo E1™ enables faster detection of oxygen saturation changes during low perfusion due to a variety of clinical factors, including sedative or medication-induced vasoconstriction. | 04 June 2011 |
| Endocrinology News | |
| FDA Approves Marketing Of RMS Subcutaneous Needle Sets Repro-Med Systems, Inc., (REPR.PK) announced that it has received approval from the Food and Drug Administration (FDA) to begin U.S. marketing of its new Subcutaneous Needle Sets which the company is promoting as the HIgh Flo™ RMS Subcutaneous Needle Sets. | 04 June 2011 |
| GastroIntestinal / Gastroenterology News | |
| Following Colorectal Cancer Surgery, Longer Delay To Beginning Chemotherapy Associated With Worse Survival An analysis of data from previously published studies indicates that longer time to beginning adjuvant chemotherapy after surgery for colorectal cancer is associated with worse survival, according to a study in the June 8 issue of JAMA, a theme issue on cancer. | 04 June 2011 |
| Genetics News | |
| Understanding Cancer Energetics It's long been known that cancer cells eat a lot of sugar to stay alive. In fact, where normal, noncancerous cells generate energy from using some sugar and a lot of oxygen, cancerous cells use virtually no oxygen and a lot of sugar. | 04 June 2011 |
| Matching Targeted Therapies To Tumor's Specific Gene Mutations May Be Key To Personalized Cancer Treatment Customizing targeted therapies to each tumor's molecular characteristics, instead of a one-size-fits-all approach by tumor type, may be more effective for some types of cancer, according to research conducted by The University of Texas MD Anderson Cancer Center. | 04 June 2011 |
| Study Identifies Genetic Mutations Associated With Cancer Risk For Hereditary Cancer Syndrome Among various genetic mutations for individuals with Lynch syndrome, a hereditary cancer syndrome that carries a high risk of colon cancer and an above-normal risk of other cancers, researchers have identified mutations associated with a lower cancer risk and mutations associateded with an increased risk for ovarian and endometrial cancer, according to a study in the June 8 issue of JAMA, a theme issue on cancer. | 04 June 2011 |
| Gout News | |
| Lower Doses Of Anti-Gout Drug Recommended Health professionals should ensure they are prescribing correct doses of colchicine, atreatment for acute gout, after three elderly patients were hospitalised within a fortnight,doctors at St Vincent's Hospital in Sydney say in a letter published in the Medical Journal ofAustralia. | 04 June 2011 |
| Hearing / Deafness News | |
| House Research Institute Family Camp Offers Weekend Of Fun For Children With Hearing Loss And Their Families Celebrating its' 26th anniversary, House Research Institute's Family Camp continues to be a popular program for many families who have a child with a hearing loss. The camp is once again filled to capacity setting an attendance record. | 04 June 2011 |
| Heart Disease News | |
| Mount Sinai Medical Center Selected To Participate In CoreValve® Clinical Trial Mount Sinai Medical Center in Miami Beach, Florida announced its participation in the Medtronic CoreValve U.S. Clinical Trial, which will evaluate a new, non-surgical alternative to open-heart surgery for patients with severe aortic stenosis. | 04 June 2011 |
| Pulmonary Thromboembolism Deaths And Obesity May Be Linked More people are dying from pulmonary thromboembolism (PTE), and this could be associated with parallel rises in obesity rates, researchers from the University of Adelaide Roger Byard wrote in the Medical Journal of AustraliaProfessor Roger Byard and co-author explain that while focus should continue on illnesses and conditions linked to obesity, such as cardiac disease, hypertension (high blood pressure), and diabetes mellitus, doctors should also concentrate on PTE. | 04 June 2011 |
| HIV / AIDS News | |
| 25% Drop In New HIV Infections Between 2001 And 2009 Worldwide Between 2001 and 2009 the number of new HIV infections per year dropped almost 25%, according to UNAIDS, the Joint United Nations Program on HIV/AIDS. During this period India's annual rate went down by over 50%, and 35% in South Africa. | 04 June 2011 |
| Immune System / Vaccines News | |
| Vaccine First To Show Improved Survival Rates For Metastatic Melanoma For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 can improve response rate and progression-free survival. | 04 June 2011 |
| Litigation / Medical Malpractice News | |
| Jack Kevorkian Preyed On Individuals With Disabilities Without Terminal Illnesses Michigan pathologist, Jack Kevorkian, nicknamed "Dr. Death" for his stance on assisted suicide and euthanasia in the USA, died aged 83 in a hospital in Detroit. Kevorkian admitted to helping over 100 patients end their lives. | 04 June 2011 |
| Jacob "Jack" Kevorkian Dies; Death With Dignity Proponent Remembered Jacob "Jack" Kevorkian, otherwise known as "Doctor Death" fell victim Friday to a blood clot that released from his leg and lodged in his heart, assumed to be complications of kidney problems for which he was admitted to a hospital for in May of this year. | 04 June 2011 |
| Lung Cancer News | |
| Talactoferrin Benefits Broad Range Of Lung Cancer Patients The investigational immunomodulatory agent talactoferrin boosts survival compared to placebo in multiple prognostically important subsets of patients with non-small cell lung cancer (NSCLC) who have failed first- or second-line therapy, according to phase II data released at the 2011 American Society of Clinical Oncology (ASCO) meeting. | 04 June 2011 |
| Lymphoma / Leukemia / Myeloma News | |
| Medco Partners With MolecularMD On Personalized Medicine Program For Chronic Myeloid Leukemia Medco Health Solutions, Inc. (NYSE: MHS) and MolecularMD Corp. announce the launch of a personalized medicine program for chronic myeloid leukemia (CML) patients. Through this program, Medco will offer patients diagnosed with CML a molecular test known as qRT-PCR (quantitative real-time polymerase chain reaction) BCR-ABL to monitor the disease. | 04 June 2011 |
| Wake Forest Baptist Medical Center And Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial Of CPI-613 In Acute Myeloid Leukemia Cornerstone Pharmaceuticals and Wake Forest Baptist Medical Center announced key findings from a Phase I clinical trial of Cornerstone's first-in-class cancer metabolism inhibitor drug, CPI-613 in Acute Myeloid Leukemia (AML). | 04 June 2011 |
| Medical Devices / Diagnostics News | |
| FDA Approves Marketing Of RMS Subcutaneous Needle Sets Repro-Med Systems, Inc., (REPR.PK) announced that it has received approval from the Food and Drug Administration (FDA) to begin U.S. marketing of its new Subcutaneous Needle Sets which the company is promoting as the HIgh Flo™ RMS Subcutaneous Needle Sets. | 04 June 2011 |
| Masimo Initiates Limited Market Release Of E1, Single-Patient-Use Ear Sensor For Pulse Oximetry Monitoring Masimo (NASDAQ: MASI) announced FDA 510(k) Clearance, CE Mark, and limited market release of the industry's first single-patient-use ear sensor. Compared to digit sensors, the Masimo E1™ enables faster detection of oxygen saturation changes during low perfusion due to a variety of clinical factors, including sedative or medication-induced vasoconstriction. | 04 June 2011 |
| Melanoma / Skin Cancer News | |
| Vaccine First To Show Improved Survival Rates For Metastatic Melanoma For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 can improve response rate and progression-free survival. | 04 June 2011 |
| Childhood Cancer Survivors At Increased Risk Of Certain Tumors In Middle-Age In a study that included nearly 18,000 children who had cancer, with follow-up of about 25 years, the greatest excess risk associated with a subsequent primary neoplasm (a new tumor) at older than age 40 years was for digestive and genitourinary neoplasms (related to the genital or urinary tract organs), according to a study in the June 8 issue of JAMA, a theme issue on cancer. | 04 June 2011 |
| MRI / PET / Ultrasound News | |
| Ovarian Cancer Screening Does Not Appear To Reduce Risk Of Ovarian Cancer Death In a clinical trial that included nearly 80,000 women, those who received ovarian cancer screening did not have a reduced risk of death from ovarian cancer compared to women who received usual care, but did have an increase in invasive medical procedures and associated harms as a result of being screened, according to a study in the June 8 issue of JAMA, a theme issue on cancer. | 04 June 2011 |
| MRSA / Drug Resistance News | |
| New MRSA Staph Strand Found In UK Cows; Pasteurized Milk Is Safe A new variant of meticilin-resistant Staphylococcus aureus found in cow's milk is genetically different to existing MRSA strains from the United Kingdom (UK). The original scare had Europeans not drinking milk, but a released study mentions that cows may simply be hosts to this new strand and normal processes of milk, such as pasteurization, will kill any risk to humans. | 04 June 2011 |
| Obesity / Weight Loss / Fitness News | |
| Psychological Approaches Key To Tackling Obesity A report on obesity published by the British Psychological Society today, 3 June, has highlighted the added value psychological and therapeutic approaches can provide when integrated effectively in obesity treatments. | 04 June 2011 |
| Pulmonary Thromboembolism Deaths And Obesity May Be Linked More people are dying from pulmonary thromboembolism (PTE), and this could be associated with parallel rises in obesity rates, researchers from the University of Adelaide Roger Byard wrote in the Medical Journal of AustraliaProfessor Roger Byard and co-author explain that while focus should continue on illnesses and conditions linked to obesity, such as cardiac disease, hypertension (high blood pressure), and diabetes mellitus, doctors should also concentrate on PTE. | 04 June 2011 |
| Ovarian Cancer News | |
| EntreMed's ENMD-2076 Demonstrates Clinical Activity In Recurrent, Platinum-Resistant Ovarian Cancer Patients EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients. | 04 June 2011 |
| Ovarian Cancer Screening Does Not Appear To Reduce Risk Of Ovarian Cancer Death In a clinical trial that included nearly 80,000 women, those who received ovarian cancer screening did not have a reduced risk of death from ovarian cancer compared to women who received usual care, but did have an increase in invasive medical procedures and associated harms as a result of being screened, according to a study in the June 8 issue of JAMA, a theme issue on cancer. | 04 June 2011 |
| Palliative Care / Hospice Care News | |
| Jack Kevorkian Preyed On Individuals With Disabilities Without Terminal Illnesses Michigan pathologist, Jack Kevorkian, nicknamed "Dr. Death" for his stance on assisted suicide and euthanasia in the USA, died aged 83 in a hospital in Detroit. Kevorkian admitted to helping over 100 patients end their lives. | 04 June 2011 |
| Pediatrics / Children's Health News | |
| Childhood Cancer Survivors At Increased Risk Of Certain Tumors In Middle-Age In a study that included nearly 18,000 children who had cancer, with follow-up of about 25 years, the greatest excess risk associated with a subsequent primary neoplasm (a new tumor) at older than age 40 years was for digestive and genitourinary neoplasms (related to the genital or urinary tract organs), according to a study in the June 8 issue of JAMA, a theme issue on cancer. | 04 June 2011 |
| Pharma Industry / Biotech Industry News | |
| Medco Partners With MolecularMD On Personalized Medicine Program For Chronic Myeloid Leukemia Medco Health Solutions, Inc. (NYSE: MHS) and MolecularMD Corp. announce the launch of a personalized medicine program for chronic myeloid leukemia (CML) patients. Through this program, Medco will offer patients diagnosed with CML a molecular test known as qRT-PCR (quantitative real-time polymerase chain reaction) BCR-ABL to monitor the disease. | 04 June 2011 |
| Wake Forest Baptist Medical Center And Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial Of CPI-613 In Acute Myeloid Leukemia Cornerstone Pharmaceuticals and Wake Forest Baptist Medical Center announced key findings from a Phase I clinical trial of Cornerstone's first-in-class cancer metabolism inhibitor drug, CPI-613 in Acute Myeloid Leukemia (AML). | 04 June 2011 |
| Everist Genomics Announces New Data On OncoDefender™- CRC Test For Predicting Recurrence Risk For Stage I And II Colorectal Cancer Patients Everist Genomics announced updated results from a study of its OncoDefender-CRC assay, a molecular prognostic test for early-stage colorectal cancer patients, will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2011, in Chicago. | 04 June 2011 |
| EntreMed's ENMD-2076 Demonstrates Clinical Activity In Recurrent, Platinum-Resistant Ovarian Cancer Patients EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients. | 04 June 2011 |
| Primary Care / General Practice News | |
| General Practice Training - What Lies Ahead? Australia A supplement in the latest Medical Journal of Australia examines the past and the future forgeneral practice training, including challenges in areas such as keeping training programs upto-date, Indigenous health, rural and remote health, aged care and military medicine. | 04 June 2011 |
| Psychology / Psychiatry News | |
| Letters From Home May Help Prevent Posttraumatic Stress Disorder In Happily Married Soldiers A new study from The Journal of Traumatic Stress finds that for active-duty male soldiers in the U.S. Army who are happily married, communicating frequently with one's spouse through letters and emails during deployment may protect against the development of posttraumatic stress disorder (PTSD) symptoms after returning home. | 04 June 2011 |
| Psychological Approaches Key To Tackling Obesity A report on obesity published by the British Psychological Society today, 3 June, has highlighted the added value psychological and therapeutic approaches can provide when integrated effectively in obesity treatments. | 04 June 2011 |
| Public Health News | |
| Jack Kevorkian Preyed On Individuals With Disabilities Without Terminal Illnesses Michigan pathologist, Jack Kevorkian, nicknamed "Dr. Death" for his stance on assisted suicide and euthanasia in the USA, died aged 83 in a hospital in Detroit. Kevorkian admitted to helping over 100 patients end their lives. | 04 June 2011 |
| General Practice Training - What Lies Ahead? Australia A supplement in the latest Medical Journal of Australia examines the past and the future forgeneral practice training, including challenges in areas such as keeping training programs upto-date, Indigenous health, rural and remote health, aged care and military medicine. | 04 June 2011 |
| Regulatory Affairs / Drug Approvals News | |
| FDA Approves Marketing Of RMS Subcutaneous Needle Sets Repro-Med Systems, Inc., (REPR.PK) announced that it has received approval from the Food and Drug Administration (FDA) to begin U.S. marketing of its new Subcutaneous Needle Sets which the company is promoting as the HIgh Flo™ RMS Subcutaneous Needle Sets. | 04 June 2011 |
| Masimo Initiates Limited Market Release Of E1, Single-Patient-Use Ear Sensor For Pulse Oximetry Monitoring Masimo (NASDAQ: MASI) announced FDA 510(k) Clearance, CE Mark, and limited market release of the industry's first single-patient-use ear sensor. Compared to digit sensors, the Masimo E1™ enables faster detection of oxygen saturation changes during low perfusion due to a variety of clinical factors, including sedative or medication-induced vasoconstriction. | 04 June 2011 |
| Respiratory / Asthma News | |
| Talactoferrin Benefits Broad Range Of Lung Cancer Patients The investigational immunomodulatory agent talactoferrin boosts survival compared to placebo in multiple prognostically important subsets of patients with non-small cell lung cancer (NSCLC) who have failed first- or second-line therapy, according to phase II data released at the 2011 American Society of Clinical Oncology (ASCO) meeting. | 04 June 2011 |
| Sexual Health / STDs News | |
| 25% Drop In New HIV Infections Between 2001 And 2009 Worldwide Between 2001 and 2009 the number of new HIV infections per year dropped almost 25%, according to UNAIDS, the Joint United Nations Program on HIV/AIDS. During this period India's annual rate went down by over 50%, and 35% in South Africa. | 04 June 2011 |
| Tuberculosis News | |
| Refugees Can Be Effectively Treated To Prevent Tuberculosis Almost one in three recently arrived refugees in Darwin tested positive for latent tuberculosisinfection (LTBI), research published in the latest Medical Journal of Australia has found. Researchers from the Centre for Disease Control, Northern Territory (CDC-NT) found that of458 refugees screened between 1 February 2006 and 31 January 2009, 146 (31. | 04 June 2011 |
| Vascular News | |
| Immune Cells Secrete A Signal Molecule That Promotes Atherosclerosis Atherosclerosis is the most common cause of cardiovascular disease, and results from chronic inflammation of arterial vessel walls. An international collaboration led by Professor Christian Weber of Ludwig-Maximilians-Universität (LMU) in Munich and Privatdozentin Alma Zernecke of Würzburg University now shows that dendritic cells stimulate this process by derailing a mechanism that normally acts as a brake on immune reactions. | 04 June 2011 |
| Veterans / Ex-Servicemen News | |
| Letters From Home May Help Prevent Posttraumatic Stress Disorder In Happily Married Soldiers A new study from The Journal of Traumatic Stress finds that for active-duty male soldiers in the U.S. Army who are happily married, communicating frequently with one's spouse through letters and emails during deployment may protect against the development of posttraumatic stress disorder (PTSD) symptoms after returning home. | 04 June 2011 |
| Women's Health / Gynecology News | |
| Leading Breast Cancer Researcher And Study Co-Author Rowan T. Chlebowski Explains Seemingly Contradictory Findings On Estrogen And Breast Cancer Rowan T. Chlebowski, M.D., Ph.D., a principal investigator at the Los Angeles Biomedical Research Institute (LA BioMed), provided his assessment of the seeming contradictions between a previous Women's Health Initiative (WHI) study and a new abstract to be presented June 4 at the 2011 American Society of Clinical Oncology. | 04 June 2011 |
| Ovarian Cancer Screening Does Not Appear To Reduce Risk Of Ovarian Cancer Death In a clinical trial that included nearly 80,000 women, those who received ovarian cancer screening did not have a reduced risk of death from ovarian cancer compared to women who received usual care, but did have an increase in invasive medical procedures and associated harms as a result of being screened, according to a study in the June 8 issue of JAMA, a theme issue on cancer. | 04 June 2011 |
| You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y . |
Tidak ada komentar:
Posting Komentar